Thermo Fisher (NYSE: TMO) to acquire Sanofi’s New Jersey manufacturing site

Thermo Fisher Scientific Inc. (NYSE: TMO) will acquire Sanofi ’s (NASDAQ: SNY) steriles manufacturing site in Ridgefield, New Jersey, expanding their strategic partnership to increase U.S. drug product manufacturing capacity. The financial terms of the deal were not disclosed.

The Ridgefield facility is a sterile fill-finish and packaging site with more than 200 employees who will join Thermo Fisher upon completion of the transaction. Thermo Fisher will continue manufacturing a portfolio of therapies for Sanofi while expanding the site’s use to serve additional pharmaceutical and biotech customers.

“Sanofi’s Ridgefield site will strengthen our U.S. manufacturing capabilities, enabling us to better support our pharmaceutical and biotech customers with the critical production capacity needed for essential medicines,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher.

Brendan O’Callaghan, global head of manufacturing and supply at Sanofi, stated the partnership expansion “will help ensure a continued supply of high-quality Sanofi products, maintaining our commitment to American manufacturing and supporting our customers and patients in the U.S.”

The acquisition adds to Thermo Fisher’s existing sterile fill-finish manufacturing network, which includes U.S. sites in Greenville, North Carolina and Plainville, Massachusetts. These facilities are part of the company’s drug development and manufacturing services for biotech and pharmaceutical companies.

The transaction is expected to close in the second half of 2025, subject to customary closing conditions. Upon completion, the Ridgefield facility will become part of Thermo Fisher’s pharma services business within its Laboratory Products and Biopharma Services segment.